Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Contamination Rate of Cryopreserved Umbilical Cord Blood Is Inversely Correlated with Volume of Sample Collected and Is also Dependent on Delivery Mode.

Stem cells translational medicine·2022

Same author

Association of systemic antibody response against polyethylene terephthalate with inflammatory serum cytokine profile following implantation of differently coated vascular prostheses in a rat animal model.

Journal of biomedical materials research. Part A·2021

Same author

Colorectal cancer risk in families with Birt-Hogg-Dubé syndrome increased.

European journal of cancer (Oxford, England : 1990)·2021

Same author

Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro.

Anticancer research·2010

Same author

Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.

Anticancer research·2010

Same author

Time course of fibronectin in the peri-implant tissue and neointima formation after functional implantation of polyester-based vascular prostheses with different porosity in pigs.

Biomedical materials (Bristol, England)·2010

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

[SRC kinases in tumor therapy].

Wolfram Dempke¹, Roland Zippel

¹Klinik für Innere Medizin II (Hämato-Onkologie und Gastroenterologie), Elblandklinikum Riesa, Weinbergstraße 8, Riesa, Germany. wolfram.dempke@elblandkliniken.de

Medizinische Klinik (Munich, Germany : 1983)

|October 29, 2010

Summary

This summary is machine-generated.

Src family kinases (SFKs) are implicated in cancer progression and metastasis. While SFK-targeting therapies show promise, combination treatments are needed for greater clinical activity.

Related Experiment Videos

Last Updated: Jun 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Area of Science:

Oncology
Molecular Biology
Biochemistry

Background:

Proto-oncogene src encodes a nonreceptor tyrosine kinase involved in various cancers.
Src family kinases (SFKs) are the largest group of nonreceptor tyrosine kinases, interacting with numerous signaling pathways.
SFK activity is linked to cancer progression and metastasis, making them potential therapeutic targets.

Purpose of the Study:

To review the role of SFKs in human cancers.
To discuss the development of SFK-targeting therapies.
To evaluate the clinical efficacy of current SFK inhibitors.

Main Methods:

Literature review of studies on src and SFKs in cancer.
Analysis of clinical trial data for SFK inhibitors.
Discussion of the therapeutic potential of SFKs.

Main Results:

Mutational activation of src is rare; wild-type src has weak oncogenic potential.
SFK activity may facilitate cancer progression and metastasis by modulating other signaling proteins.
SFK inhibitors like dasatinib, bosutinib, and saracatinib are well-tolerated but show limited monotherapy activity.

Conclusions:

SFKs are promising therapeutic targets for cancer treatment.
Current SFK inhibitors have limited clinical activity as monotherapy.
Future clinical development should focus on combination therapies involving SFK inhibitors.